Authors

Make Time for Your Own Health

Although graduate medical education at many hospitals includes provisions to ensure that trainees remain physically, emotionally, and mentally healthy, few residents and fellows make use of these resources.

Undocumented Immigrants With Cancer Face Unique Care Challenges

Undocumented immigrants continue to face discriminatory policies, which affect those with cancer on emotional, financial, physical, and social levels.

Managing TLS and CRS/ICANS: Through the Lens of a First-Year Hematology/Oncology Fellow

Tumor lysis syndrome is an oncologic emergency that every clinician will likely encounter at one time or another, and managing it requires careful consideration of a number of factors.

Reducing Burnout Requires an Organizational Response

A new study suggests that reducing physician burnout requires an organizational-level response that focuses on creating of a medical practice culture that value qualities such as teamwork, open communication, and process improvement.

How to Make Clinical Decisions With AI in Oncology

Speculation on the impact of large language models or artificial intelligence in the future of health care is commonplace, causing excitement and concern.

Physicians Must Become Advocates to Play a Role in Community Oncology’s Future

Although some community oncologists may think they can do little to abate the reimbursement reform forces that are affecting their practices, there are actions they can, and should, take to influence the success of their value-based care journey that may not be part of the fundamentals of their current practice.

LSU LCMC Health Cancer Center Researchers Uncover Key Immune Differences in Triple-Negative Breast Cancer

A LSU LCMC Health Cancer Center study provides new insights that could lead to more effective, personalized treatments in TNBC.

Outcomes During BTKi Treatment for Chronic Lymphocytic Leukemia: Insights From Remote Therapeutic Monitoring

This presentation explores patient-reported experiences during treatment for chronic lymphocytic leukemia using remote monitoring tools. It compares symptom patterns between different therapies and highlights how real-world data can support better symptom management and care decisions. Overall, the findings suggest differences in patient experiences that may help guide treatment choices and improve quality of life.

Dr Wang on Updated Efficacy and Safety Data With First-Line Ivonescimab Plus Chemotherapy in TNBC

Xiaojia Wang, MD, shares responses achieved with the combination of ivonescimab plus chemotherapy in locally advanced unresectable or metastatic TNBC.

Mentoring Oncologists in the Era of Social Distancing

Mentoring is critically important to the development of young academic hematology/oncology trainees.

Five Factors That Guide How I Treat Adults with Chronic Myeloid Leukemia in Chronic Phase

Bringing Precision Medicine to Community Oncology is Going to Require Bigger Thinking

Immunotherapy Paves Path for New Standards of Care in Gastroesophageal Cancers

It is crucial to understand and interpret the results from the landmark clinical trials in the context of recent FDA approvals in gastroesophageal cancers.

Best Practices for Virtual Conference Presentations

As the autumn and winter conference season approaches, Curtis Lachowiez, MD, reflects on the impact 2020 left on the field of oncology.

Allogeneic Transplant and Gene Therapy in Sickle Cell Disease

Markus Y. Mapara, MD, PhD, of Columbia University Irving Cancer Center, discusses the use of allogeneic transplant and gene therapy for patients with sickle cell disease.

Palliative Care for Young Adults Is a Growing Reality in CRC

Although most younger patients received diagnoses of cancer of the rectum or distal colon, incidence rates are increasing across all colorectal anatomic subsites.

It’s Time to Address Patient Needs: The Changing Landscape of Colorectal Cancer Treatment

Demystifying the Role of Palliative Care in the Oncology Clinic

Despite American Society of Clinical Oncology guidelines calling for introduction of palliative care early in the course of disease, these services remain underused.

The Podcast by Fellows for Fellows

Daniel J. Hausrath, MD, discusses a collaborative effort to produce a podcast for fellows that reviews the fundamentals, core concepts, and important management approaches in the field, as determined by the latest evidence and expert opinion.

Treatment Landscape Shifts Away From Chemotherapy Toward Targeted Approaches in ALL

Novel approaches with highly active, minimally toxic agents are needed to improve upon traditional chemotherapy and possibly eliminate chemotherapy altogether in the treatment of patients with acute lymphoblastic leukemia.

Student Loan Debt, Immigration Status Often Drive Career Decisions for Fellows

Investigators from Indiana University decided to study some of the factors influencing career plans for physicians, focusing on current fellows and recent graduates of the hematology and medical oncology specialty in the United States.

Palliative Care Can Address Gaps in Oncology Landscape

Palliative medicine has evolved to become a standard for high-quality cancer care, helping patients relieve suffering throughout their journey, improving quality of life, and prolonging survivorship.

FDA Panel Gives Beti-Cel Unanimous Support of Benefit in β-thalassemia

The FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee voted unanimously in favor of the benefit of betibeglogene autotemcel for the treatment of transfusion-dependent β-thalassemia in adult and pediatric patients with a non–β0/β0 genotype.

Tumor-Killing Technology in Head and Neck Cancer

Noah Kalman, MD, MBA, details new technology for treating head and neck cancer, and ongoing trials examining therapies at Miami Cancer Institute.

Combinations Targeting PI3K/AKT/mTOR and MAPK/ERK Pathways Are Under Study in Endometrial Cancer

Combinations targeting PI3K/AKT/mTOR and MAPK/ERK pathways are under investigation to improve outcomes in patients with endometrial cancer.

Treatment Option for Adult Patients with 3L+ Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Many people living with diffuse large B-cell lymphoma (DLBCL) continue to experience significant treatment challenges. Genmab and AbbVie discuss the current DLBCL treatment landscape and an effort as part of a collaboration between the two companies for people diagnosed with relapsed or refractory DLBCL.

$3.3 Million Grant to IU Researchers Aims to Increase Colorectal Cancer Screening in Rural Indiana

Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center are addressing the low colorectal cancer screening rates in rural Indiana communities with a five-year, $3.3 million grant from the National Cancer Institute.

Reflections and Future Directions in R/R ALL

Panelists discuss collaboration strategies for chimeric antigen receptor (CAR) T-cell therapy referral, reflections on advancements in relapsed/refractory acute lymphoblastic leukemia (R/R ALL) throughout 2024, key accomplishments, and future opportunities for progress in 2025.